Fertility Study of Women With Chronic Inflammatory Rheumatism

Overview

Etiopathogenesis of Chronic inflammatory rheumatisms (CIR) includes genetic, autoimmune and environmental factors. Their impact on the quality of life is important, leading to a sometimes severe disability. Thus they are likely to affect female fertility through several mechanisms, including autoimmune since the association between immunity and fertility has already been demonstrated in other autoimmune diseases. This study wants to evaluate and compare the birth rate between CIR and control group.

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: July 2019

Detailed Description

Data collection will be carried out using a questionnaire submitted to women in charge of the rheumatology department of the University Hospital of Toulouse and having agreed to participate: – women with Rheumatoid arthritis, Psoriatic arthritis, Ankylosing spondylitis or Chronic juvenile arthritis for the chronic inflammatory rheumatism group – women with a mechanical rheumatic pathology for the control group The primary endpoint was birth rate after spontaneous or induced pregnancy in patients who attempted to procreate, in the CIR group and in the control group.

Interventions

  • Other: Questionnaire about fertility
    • Sending a questionnaire about fertility that will have to be returned to us in order to be included in the study. The questionnaires, anonymous, will be numbered according to their order of return.

Arms, Groups and Cohorts

  • patients diagnosed before age 40
    • Patient between 18 and 50 years-old with Rheumatoid arthritis, Psoriatic arthritis, Ankylosing spondylitis, Chronic juvenile arthritis, Chronic Inflammatory Rheumatism who will answer to a questionnaire about fertility
  • Control Group
    • Patient between the ages of 18 and 50 years, not diagnosed with Chronic inflammatory rheumatism, having consulted in Rheumatology for a mechanical pathology, presenting no chronic pathology, having no chemo or radiotherapy or immunosuppressive therapy, or pelvic surgery before age 40 years who will answer to a questionnaire about fertility

Clinical Trial Outcome Measures

Primary Measures

  • Birth rate after spontaneous or induced pregnancy
    • Time Frame: One day
    • Birth rate after spontaneous or induced pregnancy in women who have tried to procreate in the chronic inflammatory rheumatism group and in the control group.

Secondary Measures

  • Rates of ectopic pregnancy, early or late spontaneous miscarriage
    • Time Frame: one day
    • Rates of ectopic pregnancy, early or late spontaneous miscarriage, early or late pregnancy, children born dead, preterm birth in the CIR group and in the control group
  • Design time
    • Time Frame: One day
    • Design time in the CIR group and in the control group
  • Birth rate according to the treatments used
    • Time Frame: One day
    • Birth rate in the CIR group according to the treatments used
  • Birth rate according to the activity of the disease
    • Time Frame: One day
    • Birth rate in the CIR group according to the activity of the disease
  • Rates of desire for pregnancy
    • Time Frame: One day
    • Rates of desire for pregnancy and study of the reasons for this lack of desire for pregnancy in the CIR group and in the control group
  • Rates of sexual dysfunction
    • Time Frame: One day
    • Rates of sexual dysfunction in the CIR group and in the control group

Participating in This Clinical Trial

Inclusion Criteria

  • Patient with Rheumatoid arthritis, Psoriatic arthritis, Ankylosing spondylitis, Chronic juvenile arthritis, Chronic Inflammatory Rheumatism – Patient diagnosed before the age of 40 – Patient having given her no opposition to her participation in research – For the control group: patient not suffering from chronic inflammatory rheumatism, having consulted in Rheumatology for a mechanical pathology Exclusion Criteria:

  • Patient> 40 years old at the time of diagnosis – Patient with insufficient medical data (treatments)

Gender Eligibility: Female

study on woman fertility

Minimum Age: 18 Years

Maximum Age: 50 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • University Hospital, Toulouse
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Jean Parinaud, MD, Principal Investigator, University Hospital, Toulouse
  • Overall Contact(s)
    • Jean Parinaud, MD, 5 67 77 11 02, parinaud.j@chu-toulouse.fr

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.